Takeda and Protagonist Receive Broad FDA Approval in Rare Blood Cancer

Takeda and Protagonist Receive Broad FDA Approval in Rare Blood Cancer

Published: Monday, September 28, 2026 6:16 AM

                        Takeda Pharmaceuticals and Protagonist Therapeutics have secured a significant FDA nod for their rare blood cancer treatment, opening up a $2 billion market opportunity.
                    

URL: Click for website